Spots Global Cancer Trial Database for refractory acute leukemia

Every month we try and update this database with for refractory acute leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia	NCT01701375	Relapsed Acute ... Refractory Acut... High-Risk Myelo...	PD 0332991	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allo-Allo Tandem Bone Marrow Transplant (BMT)	NCT00984412	Refractory Acut...	Allogeneic hema...	3 Years - 50 Years	Hadassah Medical Organization
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes	NCT03235973	Leukemia, Myelo... Leukemia, Lymph...	Fludarabine-Cla...	18 Years - 70 Years	Institut Paoli-Calmettes
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia	NCT01701375	Relapsed Acute ... Refractory Acut... High-Risk Myelo...	PD 0332991	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	NCT03834961	Central Nervous... Infantile Fibro... Recurrent Acute... Refractory Acut... Solid Neoplasm	Larotrectinib S...	- 30 Years	Children's Oncology Group
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia	NCT01701375	Relapsed Acute ... Refractory Acut... High-Risk Myelo...	PD 0332991	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes	NCT03235973	Leukemia, Myelo... Leukemia, Lymph...	Fludarabine-Cla...	18 Years - 70 Years	Institut Paoli-Calmettes
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	NCT05029141	Acute Myeloid L... Refractory Acut... Relapsed Adult ...	CAHAG regimen Placebo regimen	18 Years - 69 Years	The First Affiliated Hospital of Soochow University
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome	NCT01075425	Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Chronic Myeloge...	bortezomib belinostat laboratory biom... western blottin... pharmacological... flow cytometry	18 Years -	Virginia Commonwealth University
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias	NCT06397027	Refractory Acut... Pediatric Relap...	Ziftomenib Venetoclax Azacitidine	2 Years - 21 Years	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: